Alembic Pharmaceuticals has received approval from the USFDA to market Albendazole Tablets USP (200 mg), a generic drug for treating infections caused by worms. The tablets are equivalent to Impax Laboratories' Albenza and are used for conditions like parenchymal neurocysticercosis and cystic hydatid disease. Alembic Pharma shares rose 2.79% on Thursday. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
